RT @EricTopol: The worldwide prevalence of #LongCovid, as defined by symptoms beyond 28 days, via review of all available data, is 43% [95%…
RT @EricTopol: The worldwide prevalence of #LongCovid, as defined by symptoms beyond 28 days, via review of all available data, is 43% [95%…
RT @EricTopol: The worldwide prevalence of #LongCovid, as defined by symptoms beyond 28 days, via review of all available data, is 43% [95%…
RT @EricTopol: The worldwide prevalence of #LongCovid, as defined by symptoms beyond 28 days, via review of all available data, is 43% [95%…
RT @EricTopol: The worldwide prevalence of #LongCovid, as defined by symptoms beyond 28 days, via review of all available data, is 43% [95%…
RT Bob_Wachter https://t.co/SlyexAVeeQ "RT EricTopol: The worldwide prevalence of #LongCovid, as defined by symptoms beyond 28 days, via review of all available data, is 43% [95%…"
RT EricTopol https://t.co/QLn7BSsYQ6 "The worldwide prevalence of #LongCovid, as defined by symptoms beyond 28 days, via review of all available data, is 43% [95% CI 35, 51], with marked heterogeneity among studies https://t.co/kXXBJUcvCe Bhrama
RT @EricTopol: The worldwide prevalence of #LongCovid, as defined by symptoms beyond 28 days, via review of all available data, is 43% [95%…
RT @EricTopol: The worldwide prevalence of #LongCovid, as defined by symptoms beyond 28 days, via review of all available data, is 43% [95%…
RT @EricTopol: The worldwide prevalence of #LongCovid, as defined by symptoms beyond 28 days, via review of all available data, is 43% [95%…
RT @EricTopol: The worldwide prevalence of #LongCovid, as defined by symptoms beyond 28 days, via review of all available data, is 43% [95%…
RT @EricTopol: The worldwide prevalence of #LongCovid, as defined by symptoms beyond 28 days, via review of all available data, is 43% [95%…
מטא אנליזה מכל רחבי העולם על נוכחות סימפטומים של לונג קוביד אצל מחלימים (סימפטומים שנמשכים גם לאחר יותר מ-28 ימים). הממוצע העולמי עומד על 43% מכלל המחלימים.
RT @EricTopol: The worldwide prevalence of #LongCovid, as defined by symptoms beyond 28 days, via review of all available data, is 43% [95%…
RT @EricTopol: The worldwide prevalence of #LongCovid, as defined by symptoms beyond 28 days, via review of all available data, is 43% [95%…
RT @EricTopol: The worldwide prevalence of #LongCovid, as defined by symptoms beyond 28 days, via review of all available data, is 43% [95%…
Whaaaat?! Also the heterogeneity=unsurprising. If someone really got granular I wouldn’t be surprised if we saw “outbreaks” of long COvId/ME given the historical pattern of *some* cases of ME happening in context of outbreaks.
RT @EricTopol: The worldwide prevalence of #LongCovid, as defined by symptoms beyond 28 days, via review of all available data, is 43% [95%…
RT @EricTopol: The worldwide prevalence of #LongCovid, as defined by symptoms beyond 28 days, via review of all available data, is 43% [95%…
RT @EricTopol: The worldwide prevalence of #LongCovid, as defined by symptoms beyond 28 days, via review of all available data, is 43% [95%…
RT @EricTopol: The worldwide prevalence of #LongCovid, as defined by symptoms beyond 28 days, via review of all available data, is 43% [95%…
RT @EricTopol: The worldwide prevalence of #LongCovid, as defined by symptoms beyond 28 days, via review of all available data, is 43% [95%…
RT @EricTopol: The worldwide prevalence of #LongCovid, as defined by symptoms beyond 28 days, via review of all available data, is 43% [95%…
RT @EricTopol: The worldwide prevalence of #LongCovid, as defined by symptoms beyond 28 days, via review of all available data, is 43% [95%…
RT @EricTopol: The worldwide prevalence of #LongCovid, as defined by symptoms beyond 28 days, via review of all available data, is 43% [95%…
The worldwide prevalence of #LongCovid, as defined by symptoms beyond 28 days, via review of all available data, is 43% [95% CI 35, 51], with marked heterogeneity among studies https://t.co/dFjqoz24mx @BhramarBioStat @UMRogelCancer @umichmedicine https://t
RT @giovannidalloli: Global Prevalence of Post-Acute Sequelae of COVID-19 (PASC) or Long COVID: A Meta-Analysis and Systematic Review htt…
RT @DyorsMathew: "Based on a WHO estimate of 237 million worldwide COVID-19 infections, this global pooled PASC estimate indicates that aro…
RT @DyorsMathew: "Based on a WHO estimate of 237 million worldwide COVID-19 infections, this global pooled PASC estimate indicates that aro…
"Based on a WHO estimate of 237 million worldwide COVID-19 infections, this global pooled PASC estimate indicates that around 100 million individuals currently experience or have previously experienced long-term health-related consequences of COVID-19."
RT @medrxivpreprint: Global Prevalence of Post-Acute Sequelae of COVID-19 (PASC) or Long COVID: A Meta-Analysis and Systematic Review http…
RT @katja_adolf: Global pooled prevalence estimate of #PASC #Longcovid from 29 studies is 43% (57% for hospitalized), affecting more than 1…
Global pooled prevalence estimate of #PASC #Longcovid from 29 studies is 43% (57% for hospitalized), affecting more than 100 million people worldwide with long-term effects after Covid19! Risk factors are being female and having asthma.
RT @medrxivpreprint: Global Prevalence of Post-Acute Sequelae of COVID-19 (PASC) or Long COVID: A Meta-Analysis and Systematic Review http…
Global Prevalence of Post-Acute Sequelae of COVID-19 (PASC) or Long COVID: A Meta-Analysis and Systematic Review https://t.co/Y4N3eXEU3f"
Global Prevalence of Post-Acute Sequelae of COVID-19 (PASC) or Long COVID: A Meta-Analysis and Systematic Review https://t.co/bSR9gGvSm1 #medRxiv